Park et al. found that celecoxib, a COX-2 inhibitor in leiomyoma cells, could inhibit cell proliferation through the NF-κB pathway, suggesting that COX-2 could regulate NF-κB in leiomyoma cells [32]. Here, NFKB1 is linked to leiomyoma.